T-DXd Plus Pertuzumab Could Be New Standard of Care for Advanced Breast Cancer
T-DXd plus pertuzumab can improve outcomes when compared to treatment with a taxane, trastuzumab, and pertuzumab in patients with HER2+ advanced breast cancer.
Related Articles
Children With ALL Have Worse Outcomes if They Are Overweight or Obese for a Longer Period
Children with ALL who were overweight or obese at 2 or more time points had an increased risk of relapse and death.
Relacorilant Combo Could Be New Standard for Platinum-Resistant Ovarian Cancer
Adding relacorilant to nab-paclitaxel improved survival outcomes in patients with platinum-resistant ovarian cancer.
Inavolisib Improves OS in PIK3CA-Mutant Breast Cancer
Adding inavolisib to palbociclib and fulvestrant improves OS in patients with PIK3CA-mutant, HR-positive, HER2-negative, advanced breast cancer.
The Grand Roundup
We are introducing a new way to deliver the most relevant information you need for your patients on the topics that matter most to your…
Many Top Cancer Centers Produce Misleading Ads, Study Suggests
“The results of our study suggest a concerning pattern in cancer center advertising, particularly among top-ranked institutions,” researchers wrote.
Niraparib Improves Upon AAP and ADT in mCSPC
Adding niraparib to AAP and ADT improved rPFS in mCSPC patients with HRR mutations in the phase 3 AMPLITUDE trial.
Neoadjuvant Nivolumab Prolongs OS in NSCLC
Adding nivolumab to neoadjuvant chemotherapy improved OS in patients with resectable NSCLC in the CheckMate 816 trial.
FOLFIRINOX Deemed Standard Care for Locally Advanced Pancreatic Cancer
“The fact that this study showed a significant difference in its primary end point and the objective response rate suggests that FOLFIRINOX should be considered…
Tarlatamab Deemed “Preferable” Second-Line Therapy for Small Cell Lung Cancer
Tarlatamab improved PFS and OS over chemotherapy as second-line treatment in patients with SCLC in the phase 3 DeLLphi-304 trial.
Sacituzumab Govitecan and Pembrolizumab: A New First-Line Standard for Advanced TNBC?
Sacituzumab govitecan plus pembrolizumab improves outcomes vs chemotherapy plus pembrolizumab in patients with previously untreated, PD-L1+ TNBC.